

EUSA Pharma (UK) Ltd Modern Slavery Act Statement 2018

Pursuant to Section 54 of the UK Modern Slavery Act 2015 (“Act”), EUSA Pharma (UK) Ltd and its subsidiaries (“EUSA”) are committed to preventing slavery and human trafficking in its business and supply chains. We acknowledge our responsibilities under the Act and are taking measures to ensure our business and supply chain are free from modern slavery. We provide the following statement to set out the steps taken by EUSA during the financial year ending 31st December 2018 to prevent modern slavery and human trafficking in our business and supply chains.

EUSA’s Structure

Our parent company, EUSA Pharma (UK) Ltd is based in the UK with subsidiary companies based in France, Germany, Spain, Italy, the Netherlands, Denmark and the USA.

EUSA’s Business

EUSA is a global biopharmaceutical company focused oncology and rare disease.

EUSA’s Supply Chains


Our supply chains include the manufacture and supply of active pharmaceutical ingredients and excipients for pharmaceutical products, the manufacture and packaging of finished pharmaceutical products, and the promotion, sale and distribution of finished pharmaceutical products.

Actions taken

EUSA is in the process of:

- Carrying out due diligence checks on current suppliers in our manufacturing business based in the EU with emphasis on modern slavery practices.
- Introducing anti-modern slavery compliance questions in our due diligence questionnaire used for new third parties we engage with.
- Introducing an Anti-Slavery and Human Trafficking Policy across the business.
- Developing training for its management and employees across the business.

This Statement has been approved by the Board of Directors and EUSA Pharma (UK) Ltd as of 7th November 2019.



Name: **DEV KUMAR**

Title: **DIRECTOR**

Date: **8/11/19**